Keywords: atrix, licenses, low-dose, ifn, amarillo, biosciences, signed
Atrix licenses low-dose IFN from Amarillo
Article | 02 October 2001
Amarillo Biosciences has signed a licensing agreement with AtrixLaboratories, providing the rights to an oral low-dose formulation of interferon alfa ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
